NCT/Study#
NCT06423911 /
HQP1351CG301
A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)
DISEASE GROUP:
Leukemia
current phase:
Phase III
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
